French
DeutschNatco Pharma
 | |
| Company type | Public |
|---|---|
| NSE: NATCOPHARM BSE: 524816 | |
| Industry | Pharmaceuticals |
| Founded | 1981 |
| Founder | VC Nannapaneni |
| Headquarters | , India |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Revenue |  ₹4,127 crore (US$490 million) (FY24)[3] |
| ₹1,388 crore (US$170 million) (FY24)[4] | |
| Website | natcopharma.co.in |
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad with a presence in formulation and active pharmaceutical ingredients in both domestic and international markets. The company also manufactures Agro chemical products.[5] It is a major producer of branded oncology medicines[6] cardiology, diabetology and other pharma specialty drugs.[7] The company specialises in producing complex medicines at affordable prices.[8][9] The company has a presence in 50+ countries. NATCO is a science driven company and focuses on limited competition molecules in the US. [10][11] .The company’s pharma division has 5 manufacturing facilities, 2 API and intermediate manufacturing facilities and the crop health sciences division has one formulation and one technical manufacturing facility. The company boasts of having a talent pool of 450+ scientists working out of two research centers in India. Across the globe, cancer treatment saw a sea change in early 2000s in terms of screening, diagnosis, molecular pathology, targeted therapies, immunotherapies, Bone Marrow Transplants, and supportive care. However, most of the targeted therapies were not within the reach of common man in India and many countries across the globe. Under this circumstances NATCO through their in-house R&D in the field of Generic targeted/specialty drug therapies made the products available at a fractional cost of the innovators’ drugs. Therapeutic advancements made a great positive impact on the survival and quality of life in many cancer patients and critically ill patients.
The first dedicated affordable targeted therapy in India was launched in the year 2003. Research &Development has been the backbone of the company, by cracking vital generic molecules at a cost-effective price. R&D’s achievements are not only limited to the generic drugs but also vital drug discoveries.
History
[edit]- Venkaiah Choudary Nannapaneni founded NATCO Pharma in the year 1981 with an objective of “making specialty medicines accessible to all”
- 1981 Kothur unit started functioning, it manufactures formulations
- 1986 Operations began at Nagarjuna Sagar with manufacturing of parentals
- In 1986 Chemical division commenced functioning at Mekaguda, Telangana
- 1992 NATCO Pharma went public on 1st July 1992
- 1993 Chemical division at Mekaguda, Telangana commenced with the production of API’s and intermediates
- 2003 The oncology division was launched with the flagship brand VEENAT (generic Imatinib Mesylate) for treating chronic myelogenous leukemia
- In 2008, NATCO Pharma filed its first paragraph IV filing in the US with the USFDA, [12]
- 2011 Established its subsidiary NATCOfarma do Brasil LTDA in Brazil.
- In 2012, NATCO Pharma obtained compulsory license to produce a generic version of Bayer's anti-cancer medication Nexavar.[7]
- 2013 Natco Pharma Canada Inc. was established to facilitate sales and distribution in Canada.
- 2016 The generic version of Oseltamivir Phosphate capsules was launched in USA
- In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[12]
- In 2016, NATCO Pharma launched the first Tamiflu capsule in the US market.[13]
- 2017 Started the Cardiology and Diabetology division with the launch of Dabigatran in India
- 2017 Launched Glatiramer Acetate injection and complex drug product Liposomal Doxorubicin in the USA
- In 2019, NATCO Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
- In 2022 Crop Health Sciences division launched Chlorantraniliprole (CTPR) based products.
- NATCO launched the first generic version of Revlimid in the US market
- 2023 NATCO set up its subsidiaries in Indonesia and Colombia to boost international business
- For the financial Year 2024, NATCO recorded its highest ever revenue, Earnings Before Interests Tax Depreciation and Amortization and profit after tax.
External links
[edit]References
[edit]- ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- ^ https://www.natcopharma.co.in/wp-content/uploads/2024/05/Q4EarningsPresentation2024.pdf [bare URL PDF]
- ^ https://www.natcopharma.co.in/wp-content/uploads/2024/05/Q4EarningsPresentation2024.pdf [bare URL PDF]
- ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
- ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
- ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
- ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
- ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
- ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
- ^ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
- ^ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
